Form 4: Passage Bio CEO Granted 20,000 Restricted Stock Units

Passage Bio's President and CEO, William Chou, was granted 20,000 restricted stock units, vesting over two years.

Summary

• William Chou, President and CEO of Passage BIO, Inc. (PASG), was granted 20,000 Restricted Stock Units (RSUs).
• Each RSU converts into one share of common stock on a one-for-one basis.
• The RSUs will vest in two equal tranches: 50% (10,000 units) on January 8, 2026, and the remaining 50% (10,000 units) on January 8, 2027.
• Vesting is contingent upon Mr. Chou's continued provision of service to Passage BIO on each vesting date.
• The filing notes that the reported transaction reflects a reverse stock split effected by the issuer on July 14, 2025.

Sentiment

Score: 7

Explanation: The grant of Restricted Stock Units to the CEO is generally a positive signal, aligning management's interests with shareholders and incentivizing long-term performance. It is a standard and expected compensation practice.

Positives

• The grant of 20,000 Restricted Stock Units to President and CEO William Chou aligns management's interests with shareholders, incentivizing long-term performance.
• The two-year vesting schedule encourages sustained commitment and performance from the executive leadership.

Risks

• Vesting of the Restricted Stock Units is subject to the Reporting Person's continued provision of service to the Issuer on each vesting date, meaning the units could be forfeited if service ceases.

Future Outlook

The vesting schedule for the granted Restricted Stock Units extends through January 2027, indicating a planned long-term incentive for the CEO and a commitment to future performance.

Management Comments

• The grant of 20,000 Restricted Stock Units to President and CEO William Chou is a strategic move to align executive incentives with long-term shareholder value and retain key leadership.

Industry Context

The grant of Restricted Stock Units is a common executive compensation practice in the biotechnology and pharmaceutical industries, utilized to retain key talent, incentivize performance tied to stock appreciation, and align management's interests with those of shareholders.

Comparison to Industry Standards

• The grant of RSUs to a CEO is a standard practice in the biotech industry for executive compensation, similar to grants observed at companies like BioNTech or Moderna, aiming to align leadership incentives with long-term shareholder value.
• The two-year vesting schedule is typical for such grants, promoting retention and sustained performance, comparable to vesting schedules seen in executive compensation packages across the broader pharmaceutical sector.

Related Party Transactions

• Grant of 20,000 Restricted Stock Units to William Chou, the President and CEO, as part of his executive compensation package.

Stakeholder Impact

• Shareholders: Potential positive impact due to increased alignment of the CEO's financial interests with the company's long-term stock performance.
• Employees: No direct impact on general employees is mentioned, but this reflects the company's executive compensation practices.

Next Steps

• The first tranche of 10,000 RSUs is scheduled to vest on January 8, 2026, subject to continued service.
• The second tranche of 10,000 RSUs is scheduled to vest on January 8, 2027, subject to continued service.

Key Dates

Recommendation

The grant of Restricted Stock Units to the CEO is a standard executive compensation practice designed to align management's long-term interests with shareholder value. While positive for corporate governance and incentive alignment, it does not present new fundamental information that would warrant a change in investment recommendation based solely on this filing. Investors should continue to hold and monitor the company's operational and financial performance.

Keywords

Passage BIO, PASG, Restricted Stock Units, RSU, Executive Compensation, Insider Transaction, William Chou, Stock Grant, Form 4